AstraZeneca PLC (ZEG.DE) XETRA

126.95

+0.6(+0.47%)

Updated at September 29 05:42PM

Currency In EUR

AstraZeneca PLC

Address

1 Francis Crick Avenue

Cambridge, CB2 0AA

United Kingdom of Great Britain and Northern Ireland

Phone

44 20 3749 5000

Sector

Healthcare

Industry

Drug Manufacturers - General

Employees

94300

First IPO Date

December 02, 2003

Key Executives

NameTitlePayYear Born
Mr. Pascal Claude Roland Soriot D.V.M., M.B.A.Chief Executive Officer & Executive Director6.29M1959
Dr. Aradhana Sarin M.D.Chief Financial Officer & Executive Director3.05M1974
Mr. David FredricksonExecutive Vice-President of Oncology Haematology Business Unit0N/A
Ms. Iskra ReicExecutive Vice President of International0N/A
Dr. Susan Mary Galbraith M.D., Ph.D.Executive Vice President of Oncology Haematology R&D01966
Mr. Andrew P. BarnettHead of Investor Relations0N/A
Dr. Ruud Dobber Ph.D.Executive Vice-President of BioPharmaceuticals Business Unit0N/A
Gonzalo VinaHead of Global Media Relations0N/A
Ms. Pam P. ChengEVice President of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board01970
Mr. Jeffrey Pott J.D.CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board0N/A

Description

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.